Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles

Journal of Clinical Microbiology

Volumn 49, Issue 2, 2011, Pages 586-590

  Pfaller, M ^a   Boyken, L ^a   Hollis, R ^a   Kroeger, J ^a   Messer, S ^a   Tendolkar, S ^a   Diekema, D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TREND STUDY; WILD TYPE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR;

EID: 79951496607     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02136-10     Document Type: Article

References (32)

1. Arendrup, M. C., et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
2. Balashov, S. V., R. Gardiner, S. Park, and D. S. Perlin. 2005. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J. Clin. Microbiol. 43:214-222.
3. Bueid, A., et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
4. Cannon, R. D., et al. 2009. Efflux-mediated antifungal resistance. Clin. Microbiol. Rev. 22:291-321.
5. Chen, J., H. Li, R. Li, D. Bu, and Z. Wan. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez- Tudela. 2003. A point mutation in the 14-α-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
8. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
9. Etienne, K. A., et al. 2009. Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J. Clin. Microbiol. 47:4171-4172.
10. Howard, S. J., et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.
11. Howard, S. J., et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
12. Howard, S. J., and M. C. Arendrup. 2010. Acquired antifungal resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. [Epub ahead of print.] doi:10.3109/13693786.2010.508469.
13. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148.
14. Lass-Florl, C. 2009. Azole resistance in aspergillosis: the next threat? Curr. Fungal Infect. Rep. 3:236-242.
15. Mann, P. A., et al. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob. Agents Chemother. 47:577-581.
16. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2004. Substitutions at methionine 220 in the 14α- sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.
17. Mellado, E., et al. 2005. Targeted gene disruption of the 14-α-sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob. Agents Chemother. 49:2536-2538.
18. Mellado, E., et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904. (Pubitemid 46903071)
19. Mortensen, K. L., et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain Antimicrob. Agents Chemother. 54:4545-4549.
20. Nascimento, A. M., et al. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726.
21. Pfaller, M. A., et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
22. Pfaller, M. A., et al. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
23. Rodriguez-Tudela, J. L., et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
24. Slaven, J. W., et al. 2002. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole- resistant clinical isolate. Fungal Genet. Biol. 36:199-206.
25. Snelders, E., et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS. Med. 5:e219.
26. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
27. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
28. van der Linden, J. W. M., et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
29. Verweij, P. E., E. Mellado, and W. J. G. Melchers. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
30. Verweij, P. E., S. J. Howard, W. J. G. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
31. Verweij, P. E., E. Snelders, G. H. J. Kema, E. Mellado, and W. J. G. Melchers. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
32. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.